Global Financial Private Client’s Actinium Pharmaceuticals ATNM Stock Holding History

Global Financial Private Client’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-266	Closed	-$1.97K	–	683
2022 Q3	$1.97K	Hold	266	–	–	﹤0.01%	532
2022 Q2	$1.32K	Hold	266	–	–	﹤0.01%	548
2022 Q1	$1.36K	Hold	266	–	–	﹤0.01%	560
2021 Q4	$1.6K	Hold	266	–	–	﹤0.01%	539
2021 Q3	$2.28K	Hold	266	–	–	﹤0.01%	461
2021 Q2	$2.06K	Hold	266	–	–	﹤0.01%	479
2021 Q1	$2.14K	Hold	266	–	–	﹤0.01%	428
2020 Q4	$2.08K	Hold	266	–	–	﹤0.01%	421
2020 Q3	$2.48K	Buy	+266	New	+$2.93K	﹤0.01%	384

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Global Financial Private Client's ATNM Position: Q4 2022 in Review

Global Financial Private Client sold out of Actinium Pharmaceuticals (ATNM) in Q4 2022, closing a stake of 266 shares — an estimated $1.97K sold.

Global Financial Private Client first reported a position in ATNM in Q3 2020 and held it in 9 quarters. The position peaked at $2.48K in Q3 2020. 59 funds tracked by Wall St. Rank hold ATNM as of Q4 2022.

Global Financial Private Client reported no remaining Actinium Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Global Financial Private Client sold 266 Actinium Pharmaceuticals shares in Q4 2022, an estimated $1.97K.
Global Financial Private Client first reported a position in Actinium Pharmaceuticals in Q3 2020 and held it in 9 quarters.
Global Financial Private Client's Actinium Pharmaceuticals position peaked at $2.48K in Q3 2020.
59 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2022.

Based on Global Financial Private Client's 13F filing for Q4 2022, filed 16 May 2024.